B
BioSpace
Disc’s redemption, China’s rise, Veradermics’ validation, ESMO’s headliners
0:00-17:49
China cracks down on some biotechnology ownership transfers—but will the new policy impact licensing deals?; Disc Medicine’s Phase 3 data sweep redeems rejected rare disease therapy, teeing up another FDA run; and the ESMO conference gets underway in Madrid this week, with much-anticipated data from Merck and Summit Therapeutics.
Publisher
BioSpace
Published
October 21, 2026
Duration
18 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#discsredemption #veradermicsvalidation #esmosheadliners #lifesciences
